Tine Gaziel

• Working with Genmab’s innovative portfolio of immune-oncology compounds and ADCs
• Leading and executing on early development (phase 1-2) assets, oversight and leading the conduct of FIH and phase 2 studies
• Driving cross-functional collaboration with biostatisticians, pre-clinical and clinical scientists, safety physicians and clinical pharmacologists as well as with external stakeholders, investigators and CROs.
• Leading data-driven strategic discussions and decisions from deep insights in treatment landscape
• Providing medical, oncological expertise and guidance to support clinical trial planning and execution, including protocol writing, eligibility review, medical and safety monitoring and data analysis, preparation of presentations.
• Is a mentor and leader to the trial team, providing training, guidance and support when needed.

• Medical lead on bispecific ab program (nivatrotamab) overseeing phase 1 and initiating phase 2 trials in neuroblastoma/osteosarcoma and SCLC.
• Protocol writing. Medical monitoring. Creation of database and SAP, overseeing safety data, cross-functional support
• Medical Monitor of phase 2 trials (naxitamab/omburtamab)
• Created expanded access program for naxitamab and omburtamab globally, established CRO facilitated treatment network platform.

• Medical lead of the Clinical Trial Unit, patient recruitment to early and late phase trials
• Facilitated inclusion into the Trial Nation collaboration
• Staff specialist physician in Lung Cancer team, extensive hands-on experience with clinical immuno-oncology and implementation of new immunotherapies.
• Mentoring young doctors and team, teaching staff for continued medical education
• Participation in sponsor-led advisory boards

Nordic responsible for a global phase 3 trial, 23 sites, and for a phase 2 prostate cancer trial in DK. Abemaciclib and ramucirumab

• Collaborated with cross-functional team members to solve all study related issues supporting Medical Affairs, PRA and Clinical Operations
• Responsible for medical prelaunch activities in Nordic countries and M5 including submisson of dossiers for national regulatory authorities

Breast cancer subunit Team Lead: adjuvant and palliative treatments, recruitment of patients to clinical trials, sub-investigator MONALEESA-2, Keynote-trials

• Patient care and treatment planning, solid tumors. Palliative care.

• Head & neck cancers, CNS, urogenital, breast cancer gynecological cancers
• Dedicated training in Phase I-unit, experience with phase I trials

• Phase I Unit, GI cancers, gynecological cancers, CNS Cancer

• Neurosurgery, primary and secondary CNS maligncies

• Animal models of CNS cancer and CNS hypoxia
• Worked both independently and collaboratively in fast-paced laboratory environment. Developed research protocols and procedures
• Performed statistical, qualitative, and quantitative analysis

Exchange student, medical studies